{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:32:17Z","timestamp":1784302337889,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 217685"],"award-info":[{"award-number":["CA 217685"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ygyno.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T21:59:04Z","timestamp":1663624744000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Contemporary primary treatment of women with stage II-IV low-grade serous ovarian\/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival"],"prefix":"10.1016","volume":"167","author":[{"given":"David M.","family":"Gershenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.09.005_bb0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.09.005_bb0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.09.005_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2022.09.005_bb0020","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2020.01.021","article-title":"Low-grade serous carcinoma (LGSC): a Canadian multicenter review of practice patterns and patient outcomes","volume":"157","author":"Scott","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.09.005_bb0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0050","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2017.02.029","article-title":"Hormone receptor expression profile of low-grade serous ovarian cancers","volume":"145","author":"Buttarelli","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Llaurado Fernandez","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0065","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2022.09.005_bb0070","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous Cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0080","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2022.09.005_bb0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2020.09.049","article-title":"Clinical commentary. Endocrine therapy in the management of low-grade serous ovarian\/peritoneal carcinoma: mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors","volume":"159","author":"Gershenson","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.09.005_bb0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"4","key":"10.1016\/j.ygyno.2022.09.005_bb0100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2022.09.005_bb0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/PGP.0b013e31827630eb","article-title":"Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry","volume":"32","author":"Ali","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Nickles Fader","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2013.11.016","article-title":"The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic oncology group study","volume":"132","author":"Fader","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary: Clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion","volume":"40","author":"Ahn","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0135","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomized, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2022.09.005_bb0140","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1038\/s41598-020-77075-1","article-title":"Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan","volume":"10","author":"Kang","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004347-199004000-00002","article-title":"Serous psammocarcinoma of the ovary and peritoneum","volume":"9","author":"Gilks","year":"1990","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0150","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ejso.2019.12.005","article-title":"Ovarian and peritoneal psammocarcinoma: results of a multicenter study on 25 patients","volume":"46","author":"Delhorme","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0155","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2005.06.042","article-title":"Serous psammocarcinoma of the ovary: an unusual finding","volume":"99","author":"Rettenmaier","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.005_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10397-005-0165-x","article-title":"Psammocarcinoma of the ovary: a case report and review of the literature","volume":"3","author":"Vimplis","year":"2006","journal-title":"Gynecol. Surg."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:20:54Z","timestamp":1778714454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822005911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0090825822005911"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary primary treatment of women with stage II-IV low-grade serous ovarian\/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}